Article Versions Notes

Rango E, Pastorino F, Brignole C, Mancini A, Poggialini F, Di Maria S, Zamperini C, Iovenitti G, Fallacara AL, Sabetta S, et al. The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma. Biomedicines. 2022; 10(3):659. https://doi.org/10.3390/biomedicines10030659

Rango, Enrico, Fabio Pastorino, Chiara Brignole, Arianna Mancini, Federica Poggialini, Salvatore Di Maria, Claudio Zamperini, Giulia Iovenitti, Anna Lucia Fallacara, Samantha Sabetta, and et al. 2022. "The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma" Biomedicines 10, no. 3: 659. https://doi.org/10.3390/biomedicines10030659

Rango, E., Pastorino, F., Brignole, C., Mancini, A., Poggialini, F., Di Maria, S., Zamperini, C., Iovenitti, G., Fallacara, A. L., Sabetta, S., Clementi, L., Valoti, M., Schenone, S., Angelucci, A., Ponzoni, M., Dreassi, E., & Botta, M. (2022). The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma. Biomedicines, 10(3), 659. https://doi.org/10.3390/biomedicines10030659